The company recently released an RUO RNA extraction kit, and plans to launch a liquid biopsy pan-cancer test and disease-specific NGS panels later this year.
The arrangement, which became effective August 1, covers toxicology and pharmacogenetics testing.
The MINDACT study of Agendia's MammaPrint has reported that using the tool could cut the use of chemotherapy in half.
The contract research organization said it has already used CRISPR/Cas9 editing in several customer projects and also plans to use it for internal R&D.
Researchers from both teams plan to continue to refine their findings toward creating simple PCR or other nucleic acid amplification-based assays.
In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.
Scripps Research Institute investigators peer back at the RNA world.
Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.
In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.